Side-Effect Management Nausea, constipation, reflux, fatigue, and low appetite can all interfere with maintenance
2033 (USD BILLION) FIGURE 14 GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS
If you have common thyroid conditions like nodules or a history of papillary thyroid cancer, these do not prevent GLP-1 use
Growth/differentiation factor-15 (GDF-15) Another potential therapeutic pathway for obesity pharmacotherapies is through the stress-induced cytokine GDF-15, which is expressed in multiple cell types including cardiomyocytes, adipocytes and macrophages [98]
Studies using monoclonal antibodies against GLP-1R revealed that it is mainly present in the vasculature of the kidney (Pyke et al., 2014
Badole SL, Bagul PP, Mahamuni SP, Khose RD, Joshi AC, Jangam GB, Ghule AE, Raut CG, Khedkar VM, Coutinho EC